ixekizumab


( Last Updated : June 18, 2020)
Generic Name:
ixekizumab
Project Status:
Complete
Therapeutic Area:
Ankylosing spondylitis
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Taltz
Project Line:
Reimbursement Review
Project Number:
SR0630-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details

Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.
Submission Type:
Initial
Fee Schedule:
Schedule B
Indications:
Ankylosing spondylitis
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2
Call for patient input posted August 01, 2019
Patient group input closed September 23, 2019
Clarification:

- Patient input submission received from Arthritis Consumer Experts, Canadian Arthritis Patient Alliance and Canadian Spondylitis Association
Patient input summary sent for review to patient input groups October 15, 2019
Patient group comments on input summary closed October 22, 2019
Clarification:

- Patient input summary feedback received
Submission received September 20, 2019
Submission accepted October 08, 2019
Clarification:

- Submission was not accepted for review on 4 Oct 2019

- Revised category 1 requirements received on 7 Oct 2019
Review initiated October 09, 2019
Draft CADTH review report(s) sent to sponsor December 23, 2019
Comments from sponsor on draft CADTH review report(s) received January 09, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsor February 06, 2020
Canadian Drug Expert Committee (CDEC) meeting February 19, 2020
CDEC recommendation sent to sponsor and drug plans March 03, 2020
Embargo period ended March 17, 2020
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans March 24, 2020
CDEC Final Recommendation posted March 27, 2020
Redaction requests from sponsor on draft CADTH review report(s) received April 07, 2020
Redacted CADTH review report(s) sent to sponsor and drug plans April 20, 2020
Validation of redacted CADTH review report(s) received -
Final CADTH review report(s) posted May 22, 2020

Files

Recommendation and Reasons

Clinical Report

Pharmacoeconomic Report

Patient Group Input Submissions